Treatment of multiple sclerosis and quality of life;Tratamiento de la esclerosis multiple y calidad de vida

Revista de Neurologia

Volumn 30, Issue 12, 2000, Pages 1242-1245

  Hernandez M A ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Multiple sclerosis; Quality of life; Treatment

Indexed keywords

BETA INTERFERON;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG EFFECT; HUMAN; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; QUESTIONNAIRE; REVIEW;

HUMANS; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0034674216     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3012.99517     Document Type: Conference Paper

References (31)

1. World Health Organization. The constitution of the World Health Organization, WHO. Geneva: Chron 1947; 1: 29.
2. Hernández MA. Esclerosis múltiple y calidad de vida. Rev Neurol 1996; 24: 1221-3.
3. World Health Organization. International classification of impairments, disabilities and handicaps: a manual of classification relating to consequences of disease. Geneva: WHO; 1980.
4. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997; 48: 74-80.
5. Murphy N, Confavreux C, Haas J, Koning N, Roullet E, Sailer M, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neursurg Psychiatry 1998; 65: 469-6.
6. The IFN-b Multiple Sclerosis Study Group. Interferon beta 1-b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta 1-a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
8. The PRISMS study group randomized, double-blind, placebo-controlled study of interferon beta 1-a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
9. Woollmann T, Sánchez MP, Nieto A, Hernández MA, Gonzalez MD, Barroso J. Neuropsychological improvement in multiple sclerosis patients after one year with interferon beta 1-b treatment. Multiple Sclerosis 1999; 5 (Suppl 1): 101.
10. Rothwell PM. Quality of in life multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 65: 433.
11. Lankhorst GJ, Jelles F, Smiths RCF, Polman CH, Kuik DJ, Pfennings LE, et al. Quality of life in multiple sclerosis: the disability and impact profile (DIP). J Neurol 1996; 243: 469-74.
12. Fabio RP, Choi T, Soderberg J, Hansen CR. Health-related quality of life for patients with progressive multiple sclerosis: influence of rehabilitation. Phys Ther 1997; 77: 1704-16.
13. Jonsson A, Dock J, Ravnborg MH. Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis. Acta Neurol Scand 1996; 93: 229-35.
14. Jonsson A, Korfitzen EM, Heltberg A, et al. Effect of neuropsychological treatment in patients with multiple sclerosis. Acta Neurol Scand 1993; 88: 394-400.
15. LaRocca NG, Ritvo PG, Miller DM, Fischer JS, Andrews H, Paty DW. Quality of life assessment in multiple sclerosis clinical trials: current status and strategies for improving multiple clinical trial design. In Goodkin DE, Rudick RA, eds. Multiple sclerosis. New York: Springer-Verlarg; 1996. p. 145-60.
16. Wingerchuk DM, Noseworthy JH, Weinshenker BG. Clinical outcome measures and rating scales in multiple sclerosis trials. Mayo Clin Proc 1997; 72: 1070-9.
17. Schwartz CE, Coulthard L, Cole B, Vollmer T. The quality of life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWIST analysis. Arch Neurol 1997; 54: 1475-80.
18. Pfennings L, Cohen L, van der Ploeg H, Ploman C, Lankhorst GJ. Reliability of two measures of health-related quality of life in patients with multiple sclerosis. Percep Mot Skills 1998; 87: 111-4.
19. Gianino JM, York MM, Paice JA, Short S. Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neurosci Nurs 1998; 30: 47-54.
20. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559-75.
21. Cella DF, Dineen K, Amason B, Reder A, Webster KA, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129-39.
22. Rusthoven JJ. Are quality of life, patients preferences and cost realistic outcomes for clinical trials? Support Care Cancer 1997; 5: 112-7.
23. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.
24. Monteban H, Hardens M, Vera M, et al. Quality of life measurement and FSQ. Qual Life Res 1994; 3: 87.
25. General Social Survey 1985. Ottawa: Statistics Canada.
26. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
27. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis: comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49: 1237-42.
28. Gelbert RD, Cole BF, Gelber S, Goldhirsch A. Comparing treatments using quality-adjusted survival: the Q-TWIST method. AM Stat 1995; 49: 161-9.
29. Laman H, Lankhorst GJ. Subjective weighting of disability: an approach to quality of life assessment in rehabilitation. Disabil Rehabil 1994; 16: 198-204.
30. Vickrey BG, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187-206.
31. Foley FW. Foreword: comprehensive evaluation of outcome of care in multiple sclerosis. J Neurol Rehabil 1993; 7: 85-6.